The on-again, off-again $215 million expansion of an Eli Lilly biologics plant in Ireland is on again.
The Indianapolis, Indiana-based company said Monday it will move forward with plans to add a manufacturing line at its site in Kindsdale, County Cork. It said construction should begin in coming months and commissioning will begin in 2019. The expansion is expected to add about 130 workers to the site by 2020.
Spokesperson Tamara Ann Hull said in an email that because negotiations are underway, specifics of the investment were not being released. Earlier reports put the cost at about €200 million.
Tremors of concern spread through Ireland in February when Lilly said it halted preparations for the project. That ignited speculation among some politicians that Lilly might divert funds to the U.S. after President Trump held a meeting with pharma execs in which he urged them to invest in U.S. manufacturing. Lilly’s new CEO David Ricks was at that meeting.
Weeks later, Ricks announced an $85 million expansion at an insulin device plant in Indianapolis and pointed to $850 million in capital outlays this year in the U.S. as an indicator of its commitment to investing there.
Lilly has been expanding its biopharma operations in Cork for some years. In 2012, it began construction of a 22,000-square-meter bioprocessing plant. It also has a 158,000-square-meter monoclonal antibody plant there that was completed in 2010.
The site also does API production for a host of small molecule drugs. Last year, the company said it would invest nearly $40 million (€35 million) to build a continuous manufacturing facility there. At the time it said it had invested about $740 million (€650 million) in the site in 8 years, hiring 350 employees.
By Eric Palmer
Source: Fierce Pharma
GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]
Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]
Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]